Shuchi Nahar's Weekend Blog!

  India's Biotechnology Industry Size, Opportunities, and Investments  Twitter Handle: @shuchi_nahar Link to my previous biotechnology blog: https://myweekendspot.blogspot.com/2021/05/biotechnology-way-towards-bio-based.html India’s Biotechnology Industry The Indian biotechnology industry amounted to US$ 63 billion in 2019 and is forecast to reach US$ 150 billion by 2025, with a CAGR of 16.4%. By 2025, the contribution of the Indian biotechnology industry in the global biotechnology market is expected to grow to 19% from 3% in 2017. Bio-services, which accounted for 15% of the biotechnology industry in India, is becoming a leading destination for clinical trials, contract research, and manufacturing activities in the country. • In FY20, the sector grew 15% year on year • By FY24, the contribution of the Indian biotechnology industry in the global biotechnology market is expected to grow to 19% from 3% in FY18 • India has over 4237+ biotech startups and is expected to have over

  Syngene International Limited -  Company Overview Twitter Handle: @shuchi_nahar Link to FY 2020-21 Annual Report takeaways - https://myweekendspot.blogspot.com/2021/10/syngene-international-ltd-fy2020-21.html 1. Company Overview Incorporated in 1994 as a subsidiary of Biocon, Syngene International (SIL) is a leading contract research organization (CRO), which supports R&D programs of global innovative companies   SIL offers outsourced services to support discovery and development for organizations across industrial sectors like pharmaceuticals, biopharmaceuticals, nutraceuticals, animal health, agro-chemicals, etc. It currently caters to 293 global players including Bristol-Myers Squibb (BMS), Abbott, Baxter and Amgen, among others. SIL derives 95% of its revenues from exports. Mangalore API plant is constructed and validation is expected to be completed in FY21.  In FY20, Syngene extended its biologics discovery and preclinical research capabilities in CAR-T therapy,